Last reviewed · How we verify
Inhaled prochlorperazine 5 mg
At a glance
| Generic name | Inhaled prochlorperazine 5 mg |
|---|---|
| Also known as | ADASUVE, PCZ |
| Sponsor | Alexza Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Staccato Prochlorperazine Single Dose PK Study (PHASE1)
- Staccato Prochlorperazine Thorough QT/QTc (PHASE1)
- Staccato Prochlorperazine in Migraine (Out Patient) (PHASE2)
- Staccato Prochlorperazine in Migraine (in Clinic) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inhaled prochlorperazine 5 mg CI brief — competitive landscape report
- Inhaled prochlorperazine 5 mg updates RSS · CI watch RSS
- Alexza Pharmaceuticals, Inc. portfolio CI